Background:Patients with inflammation or severe corneal pathology are often at high risk of rejecting the human donor corneas that they receive during *** goal was to determine whether cell-free implants incorporating...
详细信息
Background:Patients with inflammation or severe corneal pathology are often at high risk of rejecting the human donor corneas that they receive during *** goal was to determine whether cell-free implants incorporating phosphorylcholine-based polymer,2-methacryloyloxyethyl phosphorylcholine(MPC),which has inflammation suppressing properties,can support repair and regeneration of ulcerated,high-risk ***:Interpenetrating networks of recombinant human collagen and MPC(RHC-MPC)were fabricated into corneal implants in a certified and monitored *** open-label,first-in-human observational study was conducted following ISO 14971 and 14155:2011,the Declaration of Helsinki and relevant laws of Ukraine and India,after respective ethical approval and trial *** unilaterally blind patients,aged 36 to 76 years old,diagnosed with conditions putting them at high risk of rejecting conventional corneal transplantation,and capable of providing informed written consent were grafted and followed up for an average of two ***,RHC like native collagen is a large macromolecule and difficult to process and is ***,small,customisable analogs to collagen comprising collagen-like peptides(CLP)conjugated to polyethylene glycol(PEG)were *** CLP-PEG analogs like RHC were combined with MPC into implants and tested in mini-pig models with alkali burned corneas,a high-risk ***:One patient had an unrelated infection that necessitated re-grafting and was excluded from the *** RHC-MPC implants in the remaining six patients were stably integrated throughout the entire observational *** was regeneration of the cornea epithelium and *** vision improvement was observed in in patients with damaged corneas due to *** two weeks post-operation,RHC-MPC implanted corneas of patients with active ulcers were free from the symptoms of pain,irritation and *** the
Graft vs host disease(GVHD) is a complication of patients who are treated by hematopoietic cell *** Institutes of Health in 2005 by Working Group on Diagnosis and Staging Consensus Development Project on Criteria for ...
详细信息
Graft vs host disease(GVHD) is a complication of patients who are treated by hematopoietic cell *** Institutes of Health in 2005 by Working Group on Diagnosis and Staging Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD(cGVHD) established 2 principal categories of oral GVHD, acute and chronic. The oral mucosa may be the first site of manifestation of the disease. Clinical diagnosis needs to be confirmed by a biopsy of oral mucosa and minor salivary glands. Microscopic results have played a major role in the diagnosis and management of acute and chronic oral GVHD. Development of second malignancies is the greatest risk of oral cGVHD patients, mostly regarding squamous cell carcinoma. The focus of oral GVHD therapy is to improve symptoms and maintain oral function. The aim of this review article is to update the information on the oral GVHD in its clinical, microscopic features and their complications.
暂无评论